

# Paweł, Rajwa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9131573/publications.pdf>

Version: 2024-02-01

82  
papers

723  
citations

687363  
13  
h-index

752698  
20  
g-index

85  
all docs

85  
docs citations

85  
times ranked

745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	3.1	10
2	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>European Urology Focus</i> , 2022, 8, 752-760.	3.1	8
3	Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 109-112.	5.4	10
4	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	2
5	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. <i>European Urology Oncology</i> , 2022, 5, 138-145.	5.4	6
6	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1072-1089.	3.1	14
7	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2022, 40, 907-914.	2.2	19
8	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	2.7	6
9	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	2.1	11
10	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 95.e1-95.e6.	1.9	20
11	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	2.2	4
12	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 106.e11-106.e19.	1.6	14
13	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	2.2	19
14	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	1.9	3
15	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
16	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	4.4	11
17	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.1	3
18	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.4	26

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124.	5.4	6
20	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. <i>Scandinavian Journal of Urology</i> , 2022, 56, 85-93.	1.0	3
21	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6
22	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	3.7	1
23	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	3.1	10
24	Prognostic impact of insulin-like growth factor and its binding proteins, insulin-like growth factor binding protein 2 and 3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	1.0	3
25	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.4	7
26	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	3.8	13
27	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.8	6
28	The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer. <i>Cancers</i> , 2022, 14, 1613.	3.7	4
29	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	3.9	7
30	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	1.9	15
31	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	2.0	10
32	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	1.0	2
33	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
34	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 315-330.	1.6	15
35	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	3.1	4
36	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. <i>European Urology Open Science</i> , 2022, 40, 117-124.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 41, 35-44.	0.4	4
38	When and How Should Active Surveillance for Prostate Cancer be De-Escalated?. European Urology Focus, 2021, 7, 297-300.	3.1	8
39	Not as black as it is painted? The impact of the first wave of COVID-19 pandemic on surgical treatment of urological cancer patients in Poland – a cross-country experience. Archives of Medical Science, 2021, , .	0.9	1
40	Prognostic factors in postoperative radiotherapy for prostate cancer – tertiary center experience. Radiology and Oncology, 2021, 55, 203-211.	1.7	1
41	Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer. Frontiers in Oncology, 2021, 11, 655000.	2.8	11
42	Abdominal complex muscle in women with stress urinary incontinence – prospective case-control study. Archives of Medical Science, 2021, , .	0.9	1
43	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European Urology, 2021, 80, 549-563.	1.9	53
44	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate, 2021, 81, 765-771.	2.3	4
45	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World Journal of Urology, 2021, 39, 3771-3779.	2.2	10
46	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 1559-1568.	0.4	2
47	Impact of systemic Immune–inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e19-785.e27.	1.6	14
48	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 2021, 39, 4355-4361.	2.2	18
49	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 806-815.	1.6	7
50	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 764-773.	1.6	14
51	The Prognostic Association of Prostate MRI PI-RADS, v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 206, 507-516.	0.4	22
52	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	5.4	40
53	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. Journal of Personalized Medicine, 2021, 11, 1231.	2.5	5
54	Adjuvant immunotherapy versus tyrosine kinase inhibitors in patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes. European Urology Open Science, 2021, 33, S333-S334.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 484-490.	0.3	2
56	Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy. Archives of Medical Science, 2020, 16, 1062-1071.	0.9	16
57	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. Journal of Clinical Medicine, 2020, 9, 3306.	2.4	4
58	Changing patterns of urologic emergency visits and admissions during the COVID-19 pandemic: a retrospective, multicenter, nationwide study. Archives of Medical Science, 2020, 17, 1262-1276.	0.9	7
59	Neutrophil-to-mean platelet volume ratio as a new predictor for overall and cancer-specific survival in patients with localized clear cell renal cell carcinoma. Archives of Medical Science, 2020, 16, 1072-1077.	0.9	1
60	Online Crowdfunding Response to Coronavirus Disease 2019. Journal of General Internal Medicine, 2020, 35, 2482-2484.	2.6	25
61	Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy. International Urology and Nephrology, 2020, 52, 885-891.	1.4	9
62	How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?. Abdominal Radiology, 2020, 45, 4031-4039.	2.1	6
63	The association between RDW and survival of patients with squamous cell carcinoma of the tongue. Simple, cheap and convenient?. Reports of Practical Oncology and Radiotherapy, 2020, 25, 494-499.	0.6	5
64	A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17511-e17511.	1.6	0
65	A blood-based multi-mRNA liquid biopsy with >90% accuracy for diagnosis and assessment of prostate cancers.. Journal of Clinical Oncology, 2020, 38, 5574-5574.	1.6	1
66	Abstract 3389: A multi-gene prostate cancer liquid biopsy with > 92% accuracy in diagnosis and assessment of disease status. , 2020, , .		0
67	Abstract 1999: Diagnostic utility of the NETest in neuroendocrine transformed prostate cancer. , 2020, , .		0
68	How has the COVID-19 pandemic impacted Polish urologists? Results from a national survey. Central European Journal of Urology, 2020, 73, 252-259.	0.3	7
69	Correlation of urinary incontinence with depression severity of patients treated for depression. Central European Journal of Urology, 2020, 73, 321-327.	0.3	1
70	The Relationship Between Red Cell Distribution Width and Cancer-Specific Survival in Patients With Renal Cell Carcinoma Treated With Partial and Radical Nephrectomy. Clinical Genitourinary Cancer, 2018, 16, e677-e683.	1.9	23
71	The comparison of oxidative stress effect in classic and tubeless percutaneous nephrolithotomy. International Urology and Nephrology, 2018, 50, 2145-2152.	1.4	2
72	Basic Parameters of Blood Count, Serum Sodium, and Creatinine as Prognostic Factors for Renal Cell Carcinoma at Five-Year Follow-Up. Medical Science Monitor, 2018, 24, 3895-3902.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. European Review for Medical and Pharmacological Sciences, 2018, 22, 3027-3037.	0.7	48
74	A non-inferiority study to analyze the safety of totally tubeless percutaneous nephrolithotomy. Advances in Clinical and Experimental Medicine, 2018, 27, 1411-1416.	1.4	2
75	Occurrence of neutrophil dysplasia in the course of severe nephrotic syndrome in a 12-year-old boy on immunosuppressive therapy: Answers. Pediatric Nephrology, 2017, 32, 605-606.	1.7	1
76	The comparison of laparoscopic and microsurgical varicocelectomy in infertile men with varicocele on paternity rate 12 months after surgery: a prospective randomized controlled trial. Andrology, 2017, 5, 445-450.	3.5	17
77	Occurrence of neutrophil dysplasia in the course of severe nephrotic syndrome in a 12-year-old boy on immunosuppressive therapy: Questions. Pediatric Nephrology, 2017, 32, 603-604.	1.7	1
78	Application of Pneumatic Lithotripter and Holmium Laser in the Treatment of Ureteral Stones and Kidney Stones in Children. BioMed Research International, 2017, 2017, 1-6.	1.9	5
79	Mechanical circulatory support in heart failure. Kardiochirurgia i Torakochirurgia Polska, 2016, 2, 130-134.	0.1	4
80	Percutaneous Nephrolithotomy with Amplatz and Alken Dilators: An Eight-Year Single Tertiary Care Centre Experience. Medical Science Monitor, 2016, 22, 4918-4923.	1.1	2
81	Postępowanie okołoperacyjne u pacjentów z wszczepionymi stentami typu DES. Folia Cardiologica, 2015, 10, 336-341.	0.1	0
82	Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. World Journal of Urology, 0, , .	2.2	3